{"gene":"KIR2DS2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2003,"finding":"Crystal structure of KIR2DS2 at 2.3 Å resolution revealed subtle displacements of two residues (Tyr45 and Gln71) compared to inhibitory KIR2DL2, explaining why KIR2DS2 does not bind HLA-Cw3 despite 99% extracellular amino acid identity with KIR2DL2. KIR tetramers confirmed KIR2DS2 fails to bind HLA-Cw3.","method":"X-ray crystallography (2.3 Å) and KIR tetramer binding assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation by KIR tetramers; foundational structural paper","pmids":["12668644"],"is_preprint":false},{"year":2000,"finding":"A naturally occurring KIR2DS2 mutant (Mp50.2) bearing six non-conservative mutations in the transmembrane region, including at the charged lysine residue, fails to associate with DAP12 adaptor molecules and cannot transduce activating signals, demonstrating that the transmembrane lysine is essential for DAP12 coupling and NK cell activation.","method":"cDNA sequencing, co-transfection assays, functional killing assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis/natural variant with in vitro reconstitution of DAP12 association and functional readout","pmids":["11169398"],"is_preprint":false},{"year":2017,"finding":"KIR2DS2 directly recognizes viral peptides derived from conserved regions of flaviviral superfamily 2 RNA helicases (including HCV, dengue, Zika, yellow fever, Japanese encephalitis) presented by HLA-C*0102 on NK cells, and this recognition is sufficient to inhibit HCV and dengue virus replication in vitro.","method":"NK cell activation assays, peptide-HLA binding assays, viral replication inhibition assays with endogenously presented peptides","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including endogenous antigen presentation and functional viral inhibition across multiple viruses","pmids":["28916719"],"is_preprint":false},{"year":2022,"finding":"Crystal structure of KIR2DS2 bound to HLA-C*0102 at 2.5 Å resolution revealed that KIR2DS2 can bind HLA-C*0102 and HLA-A*1101 in two different orientations, that Tyr45 (versus Phe45 in inhibitory KIRs) distinguishes activating from inhibitory KIR binding modes, and that a conserved 'AT' motif in the peptide mediates recognition and determines peptide specificity.","method":"X-ray crystallography (2.5 Å) of KIR2DS2/HLA-C*0102 complex","journal":"Immunology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of the receptor-ligand complex with mechanistic interpretation of key residues","pmids":["34967442"],"is_preprint":false},{"year":2017,"finding":"KIR2DS2 recognizes a β2-microglobulin-independent ligand expressed on cancer cell lines, distinct from classical HLA-C1/C2 ligands. siRNA knockdown of β2-microglobulin (>97% reduction of classical MHC-I) did not abolish KIR2DS2 reporter cell activation, and anti-HLA class I antibodies did not block recognition. Trogocytosis of membrane proteins was observed, indicating formation of KIR2DS2 ligand-specific immunological synapses.","method":"siRNA knockdown of β2-microglobulin, antibody blocking, KIR2DS2 reporter cell assay, trogocytosis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA KD, Ab blockade, reporter assay, trogocytosis) in a single study","pmids":["28202613"],"is_preprint":false},{"year":2013,"finding":"KIR2DS2+ KIR2DL2− NK cell clones are C1-reactive (HLA-C1 specific activation); however, when KIR2DS2 and KIR2DL2 are co-expressed on the same NK cell, inhibitory signaling via KIR2DL2 overrides activating signaling via KIR2DS2. In contrast, co-expression of KIR2DL1 and KIR2DS2 has an additive enhancing effect on NK cell responses.","method":"NK cell clone functional assays, FACS-based cytotoxicity/degranulation assays in cohort of 159 KIR/HLA genotyped individuals","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — functional epistasis between KIR2DS2 and KIR2DL2 established in primary NK cell clones across a large cohort","pmids":["24078689"],"is_preprint":false},{"year":2004,"finding":"Simultaneous engagement of KIR2DL3 (inhibitory) and KIR2DS2 (activating) in NK cell clones co-expressing both receptors was investigated using redirected killing assays with specific monoclonal antibodies, revealing that the functional outcome depends on the balance of activating and inhibitory signals from these co-expressed receptors.","method":"Generation of KIR2DL3-specific mAb (ECM41), redirected killing assays in NK clones co-expressing KIR2DL3 and KIR2DS2","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay with specific mAbs, but mechanism of balance not fully resolved in single study","pmids":["15314042"],"is_preprint":false},{"year":2011,"finding":"KIR2DS2*005 is a fusion gene arising from unequal crossing over between KIR2DS2 and KIR2DS3 within intron 6, resulting in a protein with the KIR2DS2 ectodomain but KIR2DS3 transmembrane/cytoplasmic regions. The fusion protein is expressed on the surface of NK and T lymphocytes as confirmed by dual monoclonal antibody detection.","method":"cDNA sequencing, population genetics, dual mAb surface expression analysis on primary NK and T cells","journal":"Genes and immunity","confidence":"Medium","confidence_rationale":"Tier 2 — molecular characterization with surface expression confirmed, but functional consequence of the hybrid transmembrane/cytoplasmic region not tested","pmids":["21593779"],"is_preprint":false},{"year":2012,"finding":"KIR2DS2 was selected evolutionarily to lose recognition of HLA-C (unlike its inhibitory counterpart KIR2DL2/3 which recognizes the C1 epitope), establishing that activating and inhibitory paralogs within the KIR2DL2/KIR2DS2 pair have divergent HLA-C binding capacities due to structural differences.","method":"Comparative functional and phylogenetic analysis of KIR2DS2, KIR2DL2, KIR2DL3 specificity and avidity for HLA-C","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 3 — review/comparative analysis synthesizing prior binding data; mechanistic interpretation is inferential","pmids":["23189078"],"is_preprint":false},{"year":2012,"finding":"KIR2DS2 promoter contains a CpG island (−160 to +26, six cytosine sites) that undergoes hypomethylation correlated with increased KIR2DS2 mRNA expression, and this hypomethylation increases after hematopoietic cell transplantation, suggesting promoter methylation as a regulatory mechanism for KIR2DS2 expression.","method":"Sodium bisulfite conversion and sequencing of CpG islands, quantitative RT-PCR for KIR2DS2 mRNA","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct methylation mapping correlated with expression, but causality not formally established by methylation manipulation","pmids":["22939905"],"is_preprint":false},{"year":2014,"finding":"KIR2DS2+ NK cells exhibit enhanced cytotoxicity against glioblastoma (GBM), retaining higher CD69 and CD16 surface expression and secreting more CD107a, granzyme A, and soluble CD137 upon contact with GBM cells. KIR2DS2+ donor NK cells significantly prolonged survival in GBM xenograft NOD/SCID mice. NK cell-mediated GBM killing was partially dependent on NKG2D ligand expression and partially abrogated by anti-NKG2D antibody blockade.","method":"FACS sorting, in vitro cytotoxicity assays, degranulation/activation marker analysis, antibody blockade, NOD/SCID xenograft mouse model","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal functional assays in vitro and in vivo, though KIR2DS2-specific ligand on GBM not identified","pmids":["25381437"],"is_preprint":false},{"year":2022,"finding":"NK cells with high KIR2DS2 surface expression have enhanced spontaneous cytotoxicity against malignant B cell lines, liver cancer cell lines, and primary CLL cells. KIR2DS2high NK cells have increased CD16 expression and enhanced antibody-dependent cellular cytotoxicity with rituximab and obinutuzumab. Bulk and single-cell RNA sequencing confirmed upregulation of NK-mediated cytotoxicity, translation, and FCGR gene pathways in KIR2DS2high cells.","method":"Flow cytometry, ADCC functional assays, bulk RNA-seq, novel single-cell RNA-seq technique for KIR2DS2+ identification","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods including transcriptomics and functional assays, but mechanism of KIR2DS2-enhanced CD16 expression not resolved","pmids":["35768150"],"is_preprint":false}],"current_model":"KIR2DS2 is an activating NK cell receptor that signals through a transmembrane lysine residue essential for DAP12 adaptor association; its crystal structure (and complex structure with HLA-C*0102) reveals that Tyr45 distinguishes it from inhibitory KIR paralogs and underlies its divergent HLA-C binding, with KIR2DS2 recognizing HLA-C1-presented viral helicase peptides (from HCV and flaviviruses) to activate NK cells and inhibit viral replication, while also engaging a β2-microglobulin-independent ligand on cancer cells; when co-expressed with inhibitory KIR2DL2, inhibitory signaling dominates, but KIR2DS2high NK cells show enhanced cytotoxicity and ADCC."},"narrative":{"teleology":[{"year":2000,"claim":"Establishing how KIR2DS2 couples to activating signaling: a natural transmembrane mutant demonstrated that the charged lysine residue is essential for DAP12 association and activating signal transduction, defining the molecular basis of KIR2DS2's stimulatory function.","evidence":"cDNA sequencing of natural variant Mp50.2 with co-transfection and functional killing assays","pmids":["11169398"],"confidence":"High","gaps":["Whether other transmembrane residues contribute to DAP12 coupling beyond the lysine","Stoichiometry of the KIR2DS2–DAP12 complex not determined"]},{"year":2003,"claim":"Resolving why KIR2DS2 does not bind HLA-Cw3 despite near-identical sequence to inhibitory KIR2DL2: the 2.3 Å crystal structure identified Tyr45 and Gln71 displacements as the structural basis for divergent ligand recognition.","evidence":"X-ray crystallography at 2.3 Å with KIR tetramer binding validation","pmids":["12668644"],"confidence":"High","gaps":["What physiological ligands KIR2DS2 does engage remained unknown at this stage","Whether Tyr45 alone is sufficient to abolish HLA-C binding was not tested by mutagenesis"]},{"year":2004,"claim":"Determining the functional outcome when activating and inhibitory KIR receptors are co-expressed: redirected killing assays showed that simultaneous KIR2DL3 and KIR2DS2 engagement produces an outcome governed by signal balance.","evidence":"KIR2DL3-specific mAb ECM41 in redirected killing assays of NK clones co-expressing both receptors","pmids":["15314042"],"confidence":"Medium","gaps":["Quantitative parameters (threshold ratios) governing activating vs. inhibitory dominance not defined","Downstream signaling integration mechanism not characterized"]},{"year":2013,"claim":"Clarifying the epistatic hierarchy between KIR2DS2 and KIR2DL2: KIR2DS2+KIR2DL2− NK cells are C1-reactive, but co-expression of KIR2DL2 overrides KIR2DS2 activation, establishing inhibitory dominance within this paralog pair.","evidence":"Functional assays on NK cell clones from 159 KIR/HLA-genotyped individuals","pmids":["24078689"],"confidence":"High","gaps":["Molecular mechanism of inhibitory signal dominance (e.g., phosphatase recruitment kinetics) not resolved","Whether licensing status modulates this dominance hierarchy"]},{"year":2017,"claim":"Identifying the first physiological ligand: KIR2DS2 directly recognizes conserved flaviviral RNA helicase peptides presented by HLA-C*0102, sufficient to activate NK cells and inhibit HCV and dengue virus replication, establishing KIR2DS2 as a peptide-selective activating receptor in antiviral immunity.","evidence":"NK activation assays, peptide-HLA binding assays, and viral replication inhibition assays with endogenous antigen presentation","pmids":["28916719"],"confidence":"High","gaps":["In vivo relevance for viral clearance in human infection not established","Whether KIR2DS2 discriminates additional non-viral peptides on HLA-C*0102"]},{"year":2017,"claim":"Revealing a non-classical ligand on cancer cells: KIR2DS2 recognizes a β2-microglobulin-independent surface molecule on tumor cell lines, broadening its ligand repertoire beyond classical MHC class I.","evidence":"siRNA knockdown of β2-microglobulin, anti-HLA blocking antibodies, KIR2DS2 reporter cell assays, and trogocytosis","pmids":["28202613"],"confidence":"High","gaps":["Molecular identity of the β2-microglobulin-independent tumor ligand unknown","Whether this ligand is tumor-specific or also expressed on normal cells"]},{"year":2022,"claim":"Structural resolution of peptide-selective recognition: the 2.5 Å KIR2DS2–HLA-C*0102 complex structure showed dual binding orientations and identified Tyr45 and a conserved 'AT' peptide motif as determinants of activating versus inhibitory KIR specificity.","evidence":"X-ray crystallography at 2.5 Å of the receptor–pHLA complex","pmids":["34967442"],"confidence":"High","gaps":["Functional consequences of the two binding orientations for signaling not tested","Whether the AT motif is necessary and sufficient for activation not confirmed by alanine scanning in cellular assays"]},{"year":2022,"claim":"Linking KIR2DS2 surface density to effector function: KIR2DS2high NK cells exhibit enhanced spontaneous cytotoxicity and ADCC, with transcriptomic upregulation of cytotoxicity and FCGR pathways, positioning KIR2DS2 expression level as a determinant of NK cell antitumor potency.","evidence":"Flow cytometry, ADCC assays with rituximab/obinutuzumab, bulk and single-cell RNA-seq","pmids":["35768150"],"confidence":"Medium","gaps":["Causal mechanism linking KIR2DS2 expression to CD16 upregulation not established","Whether KIR2DS2high phenotype is stable or dynamically regulated"]},{"year":null,"claim":"The molecular identity of the β2-microglobulin-independent tumor ligand, the in vivo significance of peptide-selective recognition for viral clearance, and the mechanism by which KIR2DS2 expression level modulates broader NK effector programs remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["β2-microglobulin-independent ligand identity unknown","No in vivo demonstration of KIR2DS2-dependent viral control in human infection","Signaling pathway downstream of DAP12 specific to KIR2DS2 not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,4,5]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,7]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5,10,11]}],"complexes":[],"partners":["DAP12","HLA-C*0102","KIR2DL2"],"other_free_text":[]},"mechanistic_narrative":"KIR2DS2 is an activating natural killer cell receptor that transmits stimulatory signals through DAP12 adaptor association mediated by a critical transmembrane lysine residue [PMID:11169398]. Crystal structures reveal that despite 99% extracellular sequence identity with its inhibitory paralog KIR2DL2, KIR2DS2 diverges in HLA-C binding due to Tyr45 displacement, enabling peptide-selective recognition of HLA-C*0102-presented viral helicase peptides from HCV and flaviviruses sufficient to inhibit viral replication [PMID:12668644, PMID:34967442, PMID:28916719]. KIR2DS2 also recognizes a β2-microglobulin-independent ligand on cancer cells, and NK cells with high KIR2DS2 expression display enhanced cytotoxicity and antibody-dependent cellular cytotoxicity against malignant targets, though co-expression with the inhibitory paralog KIR2DL2 results in dominance of inhibitory signaling [PMID:28202613, PMID:35768150, PMID:24078689]."},"prefetch_data":{"uniprot":{"accession":"P43631","full_name":"Killer cell immunoglobulin-like receptor 2DS2","aliases":["CD158 antigen-like family member J","NK receptor 183 ActI","Natural killer-associated transcript 5","NKAT-5","p58 natural killer cell receptor clone CL-49","p58 NK receptor CL-49"],"length_aa":304,"mass_kda":33.5,"function":"Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P43631/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KIR2DS2"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KIR2DS2","total_profiled":1310},"omim":[{"mim_id":"604956","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 5; KIR2DS5","url":"https://www.omim.org/entry/604956"},{"mim_id":"604955","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 4; KIR2DS4","url":"https://www.omim.org/entry/604955"},{"mim_id":"604954","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 3; KIR2DS3","url":"https://www.omim.org/entry/604954"},{"mim_id":"604953","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 2; KIR2DS2","url":"https://www.omim.org/entry/604953"},{"mim_id":"604142","title":"TYRO PROTEIN TYROSINE KINASE-BINDING PROTEIN; TYROBP","url":"https://www.omim.org/entry/604142"}],"hpa":{"profiled":false,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"","tissue_distribution":"","driving_tissues":[],"url":"https://www.proteinatlas.org/search/KIR2DS2"},"hgnc":{"alias_symbol":["cl-49","nkat5","183ActI","CD158J"],"prev_symbol":[]},"alphafold":{"accession":"P43631","domains":[{"cath_id":"2.60.40.10","chopping":"24-121","consensus_level":"high","plddt":93.9281,"start":24,"end":121},{"cath_id":"2.60.40.10","chopping":"127-220","consensus_level":"high","plddt":95.3312,"start":127,"end":220}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43631","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43631-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43631-F1-predicted_aligned_error_v6.png","plddt_mean":80.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KIR2DS2","jax_strain_url":"https://www.jax.org/strain/search?query=KIR2DS2"},"sequence":{"accession":"P43631","fasta_url":"https://rest.uniprot.org/uniprotkb/P43631.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43631/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43631"}},"corpus_meta":[{"pmid":"23189078","id":"PMC_23189078","title":"Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3.","date":"2012","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23189078","citation_count":92,"is_preprint":false},{"pmid":"24078689","id":"PMC_24078689","title":"Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24078689","citation_count":85,"is_preprint":false},{"pmid":"28916719","id":"PMC_28916719","title":"KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C.","date":"2017","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28916719","citation_count":79,"is_preprint":false},{"pmid":"12668644","id":"PMC_12668644","title":"Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j).","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12668644","citation_count":71,"is_preprint":false},{"pmid":"25381437","id":"PMC_25381437","title":"NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25381437","citation_count":52,"is_preprint":false},{"pmid":"19493232","id":"PMC_19493232","title":"Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.","date":"2009","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/19493232","citation_count":50,"is_preprint":false},{"pmid":"1969394","id":"PMC_1969394","title":"Characteristics of binding of Escherichia coli serotype O157:H7 strain CL-49 to purified intestinal mucin.","date":"1990","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/1969394","citation_count":49,"is_preprint":false},{"pmid":"1969395","id":"PMC_1969395","title":"Role of the putative \"link\" glycopeptide of intestinal mucin in binding of piliated Escherichia coli serotype O157:H7 strain CL-49.","date":"1990","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/1969395","citation_count":41,"is_preprint":false},{"pmid":"17559579","id":"PMC_17559579","title":"Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17559579","citation_count":37,"is_preprint":false},{"pmid":"28202613","id":"PMC_28202613","title":"The Activating Human NK Cell Receptor KIR2DS2 Recognizes a β2-Microglobulin-Independent Ligand on Cancer Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28202613","citation_count":31,"is_preprint":false},{"pmid":"21596150","id":"PMC_21596150","title":"Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.","date":"2011","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21596150","citation_count":30,"is_preprint":false},{"pmid":"30689576","id":"PMC_30689576","title":"KIR2DS2/KIR2DL2/HLA-C1 Haplotype Is Associated with Alzheimer's Disease: Implication for the Role of Herpesvirus Infections.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30689576","citation_count":30,"is_preprint":false},{"pmid":"30696053","id":"PMC_30696053","title":"Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as Genetic Markers for Stratifying the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30696053","citation_count":20,"is_preprint":false},{"pmid":"19877200","id":"PMC_19877200","title":"Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.","date":"2009","source":"Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society","url":"https://pubmed.ncbi.nlm.nih.gov/19877200","citation_count":17,"is_preprint":false},{"pmid":"22024796","id":"PMC_22024796","title":"The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms.","date":"2012","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/22024796","citation_count":17,"is_preprint":false},{"pmid":"27251940","id":"PMC_27251940","title":"KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients.","date":"2016","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27251940","citation_count":15,"is_preprint":false},{"pmid":"21593779","id":"PMC_21593779","title":"Molecular characterisation of KIR2DS2*005, a fusion gene associated with a shortened KIR haplotype.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21593779","citation_count":13,"is_preprint":false},{"pmid":"15314042","id":"PMC_15314042","title":"Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15314042","citation_count":13,"is_preprint":false},{"pmid":"26202659","id":"PMC_26202659","title":"Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.","date":"2015","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/26202659","citation_count":12,"is_preprint":false},{"pmid":"11169398","id":"PMC_11169398","title":"Identification and molecular characterization of a natural mutant of the p50.2/KIR2DS2 activating NK receptor that fails to mediate NK cell triggering.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11169398","citation_count":12,"is_preprint":false},{"pmid":"35768150","id":"PMC_35768150","title":"KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.","date":"2022","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/35768150","citation_count":10,"is_preprint":false},{"pmid":"34967442","id":"PMC_34967442","title":"Activating receptor KIR2DS2 bound to HLA-C1 reveals the novel recognition features of activating receptor.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34967442","citation_count":9,"is_preprint":false},{"pmid":"30381896","id":"PMC_30381896","title":"A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors.","date":"2019","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/30381896","citation_count":7,"is_preprint":false},{"pmid":"26975229","id":"PMC_26975229","title":"KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.","date":"2016","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/26975229","citation_count":4,"is_preprint":false},{"pmid":"21165439","id":"PMC_21165439","title":"Expression of KIR2DL3 and KIR2DS2 natural killer receptors in exercise.","date":"2010","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21165439","citation_count":2,"is_preprint":false},{"pmid":"22939905","id":"PMC_22939905","title":"KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22939905","citation_count":1,"is_preprint":false},{"pmid":"34155832","id":"PMC_34155832","title":"Characterization of the novel KIR2DS2*022 allele identified in a northern Chinese Han individual.","date":"2021","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/34155832","citation_count":0,"is_preprint":false},{"pmid":"39286025","id":"PMC_39286025","title":"KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39286025","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15153,"output_tokens":3163,"usd":0.046452},"stage2":{"model":"claude-opus-4-6","input_tokens":6543,"output_tokens":2181,"usd":0.13086},"total_usd":0.177312,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of KIR2DS2 at 2.3 Å resolution revealed subtle displacements of two residues (Tyr45 and Gln71) compared to inhibitory KIR2DL2, explaining why KIR2DS2 does not bind HLA-Cw3 despite 99% extracellular amino acid identity with KIR2DL2. KIR tetramers confirmed KIR2DS2 fails to bind HLA-Cw3.\",\n      \"method\": \"X-ray crystallography (2.3 Å) and KIR tetramer binding assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation by KIR tetramers; foundational structural paper\",\n      \"pmids\": [\"12668644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A naturally occurring KIR2DS2 mutant (Mp50.2) bearing six non-conservative mutations in the transmembrane region, including at the charged lysine residue, fails to associate with DAP12 adaptor molecules and cannot transduce activating signals, demonstrating that the transmembrane lysine is essential for DAP12 coupling and NK cell activation.\",\n      \"method\": \"cDNA sequencing, co-transfection assays, functional killing assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis/natural variant with in vitro reconstitution of DAP12 association and functional readout\",\n      \"pmids\": [\"11169398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"KIR2DS2 directly recognizes viral peptides derived from conserved regions of flaviviral superfamily 2 RNA helicases (including HCV, dengue, Zika, yellow fever, Japanese encephalitis) presented by HLA-C*0102 on NK cells, and this recognition is sufficient to inhibit HCV and dengue virus replication in vitro.\",\n      \"method\": \"NK cell activation assays, peptide-HLA binding assays, viral replication inhibition assays with endogenously presented peptides\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including endogenous antigen presentation and functional viral inhibition across multiple viruses\",\n      \"pmids\": [\"28916719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structure of KIR2DS2 bound to HLA-C*0102 at 2.5 Å resolution revealed that KIR2DS2 can bind HLA-C*0102 and HLA-A*1101 in two different orientations, that Tyr45 (versus Phe45 in inhibitory KIRs) distinguishes activating from inhibitory KIR binding modes, and that a conserved 'AT' motif in the peptide mediates recognition and determines peptide specificity.\",\n      \"method\": \"X-ray crystallography (2.5 Å) of KIR2DS2/HLA-C*0102 complex\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of the receptor-ligand complex with mechanistic interpretation of key residues\",\n      \"pmids\": [\"34967442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"KIR2DS2 recognizes a β2-microglobulin-independent ligand expressed on cancer cell lines, distinct from classical HLA-C1/C2 ligands. siRNA knockdown of β2-microglobulin (>97% reduction of classical MHC-I) did not abolish KIR2DS2 reporter cell activation, and anti-HLA class I antibodies did not block recognition. Trogocytosis of membrane proteins was observed, indicating formation of KIR2DS2 ligand-specific immunological synapses.\",\n      \"method\": \"siRNA knockdown of β2-microglobulin, antibody blocking, KIR2DS2 reporter cell assay, trogocytosis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA KD, Ab blockade, reporter assay, trogocytosis) in a single study\",\n      \"pmids\": [\"28202613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"KIR2DS2+ KIR2DL2− NK cell clones are C1-reactive (HLA-C1 specific activation); however, when KIR2DS2 and KIR2DL2 are co-expressed on the same NK cell, inhibitory signaling via KIR2DL2 overrides activating signaling via KIR2DS2. In contrast, co-expression of KIR2DL1 and KIR2DS2 has an additive enhancing effect on NK cell responses.\",\n      \"method\": \"NK cell clone functional assays, FACS-based cytotoxicity/degranulation assays in cohort of 159 KIR/HLA genotyped individuals\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional epistasis between KIR2DS2 and KIR2DL2 established in primary NK cell clones across a large cohort\",\n      \"pmids\": [\"24078689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Simultaneous engagement of KIR2DL3 (inhibitory) and KIR2DS2 (activating) in NK cell clones co-expressing both receptors was investigated using redirected killing assays with specific monoclonal antibodies, revealing that the functional outcome depends on the balance of activating and inhibitory signals from these co-expressed receptors.\",\n      \"method\": \"Generation of KIR2DL3-specific mAb (ECM41), redirected killing assays in NK clones co-expressing KIR2DL3 and KIR2DS2\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with specific mAbs, but mechanism of balance not fully resolved in single study\",\n      \"pmids\": [\"15314042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"KIR2DS2*005 is a fusion gene arising from unequal crossing over between KIR2DS2 and KIR2DS3 within intron 6, resulting in a protein with the KIR2DS2 ectodomain but KIR2DS3 transmembrane/cytoplasmic regions. The fusion protein is expressed on the surface of NK and T lymphocytes as confirmed by dual monoclonal antibody detection.\",\n      \"method\": \"cDNA sequencing, population genetics, dual mAb surface expression analysis on primary NK and T cells\",\n      \"journal\": \"Genes and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — molecular characterization with surface expression confirmed, but functional consequence of the hybrid transmembrane/cytoplasmic region not tested\",\n      \"pmids\": [\"21593779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIR2DS2 was selected evolutionarily to lose recognition of HLA-C (unlike its inhibitory counterpart KIR2DL2/3 which recognizes the C1 epitope), establishing that activating and inhibitory paralogs within the KIR2DL2/KIR2DS2 pair have divergent HLA-C binding capacities due to structural differences.\",\n      \"method\": \"Comparative functional and phylogenetic analysis of KIR2DS2, KIR2DL2, KIR2DL3 specificity and avidity for HLA-C\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review/comparative analysis synthesizing prior binding data; mechanistic interpretation is inferential\",\n      \"pmids\": [\"23189078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIR2DS2 promoter contains a CpG island (−160 to +26, six cytosine sites) that undergoes hypomethylation correlated with increased KIR2DS2 mRNA expression, and this hypomethylation increases after hematopoietic cell transplantation, suggesting promoter methylation as a regulatory mechanism for KIR2DS2 expression.\",\n      \"method\": \"Sodium bisulfite conversion and sequencing of CpG islands, quantitative RT-PCR for KIR2DS2 mRNA\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct methylation mapping correlated with expression, but causality not formally established by methylation manipulation\",\n      \"pmids\": [\"22939905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KIR2DS2+ NK cells exhibit enhanced cytotoxicity against glioblastoma (GBM), retaining higher CD69 and CD16 surface expression and secreting more CD107a, granzyme A, and soluble CD137 upon contact with GBM cells. KIR2DS2+ donor NK cells significantly prolonged survival in GBM xenograft NOD/SCID mice. NK cell-mediated GBM killing was partially dependent on NKG2D ligand expression and partially abrogated by anti-NKG2D antibody blockade.\",\n      \"method\": \"FACS sorting, in vitro cytotoxicity assays, degranulation/activation marker analysis, antibody blockade, NOD/SCID xenograft mouse model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays in vitro and in vivo, though KIR2DS2-specific ligand on GBM not identified\",\n      \"pmids\": [\"25381437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NK cells with high KIR2DS2 surface expression have enhanced spontaneous cytotoxicity against malignant B cell lines, liver cancer cell lines, and primary CLL cells. KIR2DS2high NK cells have increased CD16 expression and enhanced antibody-dependent cellular cytotoxicity with rituximab and obinutuzumab. Bulk and single-cell RNA sequencing confirmed upregulation of NK-mediated cytotoxicity, translation, and FCGR gene pathways in KIR2DS2high cells.\",\n      \"method\": \"Flow cytometry, ADCC functional assays, bulk RNA-seq, novel single-cell RNA-seq technique for KIR2DS2+ identification\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including transcriptomics and functional assays, but mechanism of KIR2DS2-enhanced CD16 expression not resolved\",\n      \"pmids\": [\"35768150\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KIR2DS2 is an activating NK cell receptor that signals through a transmembrane lysine residue essential for DAP12 adaptor association; its crystal structure (and complex structure with HLA-C*0102) reveals that Tyr45 distinguishes it from inhibitory KIR paralogs and underlies its divergent HLA-C binding, with KIR2DS2 recognizing HLA-C1-presented viral helicase peptides (from HCV and flaviviruses) to activate NK cells and inhibit viral replication, while also engaging a β2-microglobulin-independent ligand on cancer cells; when co-expressed with inhibitory KIR2DL2, inhibitory signaling dominates, but KIR2DS2high NK cells show enhanced cytotoxicity and ADCC.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KIR2DS2 is an activating natural killer cell receptor that transmits stimulatory signals through DAP12 adaptor association mediated by a critical transmembrane lysine residue [PMID:11169398]. Crystal structures reveal that despite 99% extracellular sequence identity with its inhibitory paralog KIR2DL2, KIR2DS2 diverges in HLA-C binding due to Tyr45 displacement, enabling peptide-selective recognition of HLA-C*0102-presented viral helicase peptides from HCV and flaviviruses sufficient to inhibit viral replication [PMID:12668644, PMID:34967442, PMID:28916719]. KIR2DS2 also recognizes a β2-microglobulin-independent ligand on cancer cells, and NK cells with high KIR2DS2 expression display enhanced cytotoxicity and antibody-dependent cellular cytotoxicity against malignant targets, though co-expression with the inhibitory paralog KIR2DL2 results in dominance of inhibitory signaling [PMID:28202613, PMID:35768150, PMID:24078689].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing how KIR2DS2 couples to activating signaling: a natural transmembrane mutant demonstrated that the charged lysine residue is essential for DAP12 association and activating signal transduction, defining the molecular basis of KIR2DS2's stimulatory function.\",\n      \"evidence\": \"cDNA sequencing of natural variant Mp50.2 with co-transfection and functional killing assays\",\n      \"pmids\": [\"11169398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transmembrane residues contribute to DAP12 coupling beyond the lysine\", \"Stoichiometry of the KIR2DS2–DAP12 complex not determined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolving why KIR2DS2 does not bind HLA-Cw3 despite near-identical sequence to inhibitory KIR2DL2: the 2.3 Å crystal structure identified Tyr45 and Gln71 displacements as the structural basis for divergent ligand recognition.\",\n      \"evidence\": \"X-ray crystallography at 2.3 Å with KIR tetramer binding validation\",\n      \"pmids\": [\"12668644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What physiological ligands KIR2DS2 does engage remained unknown at this stage\", \"Whether Tyr45 alone is sufficient to abolish HLA-C binding was not tested by mutagenesis\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Determining the functional outcome when activating and inhibitory KIR receptors are co-expressed: redirected killing assays showed that simultaneous KIR2DL3 and KIR2DS2 engagement produces an outcome governed by signal balance.\",\n      \"evidence\": \"KIR2DL3-specific mAb ECM41 in redirected killing assays of NK clones co-expressing both receptors\",\n      \"pmids\": [\"15314042\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative parameters (threshold ratios) governing activating vs. inhibitory dominance not defined\", \"Downstream signaling integration mechanism not characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Clarifying the epistatic hierarchy between KIR2DS2 and KIR2DL2: KIR2DS2+KIR2DL2− NK cells are C1-reactive, but co-expression of KIR2DL2 overrides KIR2DS2 activation, establishing inhibitory dominance within this paralog pair.\",\n      \"evidence\": \"Functional assays on NK cell clones from 159 KIR/HLA-genotyped individuals\",\n      \"pmids\": [\"24078689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of inhibitory signal dominance (e.g., phosphatase recruitment kinetics) not resolved\", \"Whether licensing status modulates this dominance hierarchy\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying the first physiological ligand: KIR2DS2 directly recognizes conserved flaviviral RNA helicase peptides presented by HLA-C*0102, sufficient to activate NK cells and inhibit HCV and dengue virus replication, establishing KIR2DS2 as a peptide-selective activating receptor in antiviral immunity.\",\n      \"evidence\": \"NK activation assays, peptide-HLA binding assays, and viral replication inhibition assays with endogenous antigen presentation\",\n      \"pmids\": [\"28916719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance for viral clearance in human infection not established\", \"Whether KIR2DS2 discriminates additional non-viral peptides on HLA-C*0102\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealing a non-classical ligand on cancer cells: KIR2DS2 recognizes a β2-microglobulin-independent surface molecule on tumor cell lines, broadening its ligand repertoire beyond classical MHC class I.\",\n      \"evidence\": \"siRNA knockdown of β2-microglobulin, anti-HLA blocking antibodies, KIR2DS2 reporter cell assays, and trogocytosis\",\n      \"pmids\": [\"28202613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of the β2-microglobulin-independent tumor ligand unknown\", \"Whether this ligand is tumor-specific or also expressed on normal cells\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Structural resolution of peptide-selective recognition: the 2.5 Å KIR2DS2–HLA-C*0102 complex structure showed dual binding orientations and identified Tyr45 and a conserved 'AT' peptide motif as determinants of activating versus inhibitory KIR specificity.\",\n      \"evidence\": \"X-ray crystallography at 2.5 Å of the receptor–pHLA complex\",\n      \"pmids\": [\"34967442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of the two binding orientations for signaling not tested\", \"Whether the AT motif is necessary and sufficient for activation not confirmed by alanine scanning in cellular assays\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linking KIR2DS2 surface density to effector function: KIR2DS2high NK cells exhibit enhanced spontaneous cytotoxicity and ADCC, with transcriptomic upregulation of cytotoxicity and FCGR pathways, positioning KIR2DS2 expression level as a determinant of NK cell antitumor potency.\",\n      \"evidence\": \"Flow cytometry, ADCC assays with rituximab/obinutuzumab, bulk and single-cell RNA-seq\",\n      \"pmids\": [\"35768150\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal mechanism linking KIR2DS2 expression to CD16 upregulation not established\", \"Whether KIR2DS2high phenotype is stable or dynamically regulated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the β2-microglobulin-independent tumor ligand, the in vivo significance of peptide-selective recognition for viral clearance, and the mechanism by which KIR2DS2 expression level modulates broader NK effector programs remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"β2-microglobulin-independent ligand identity unknown\", \"No in vivo demonstration of KIR2DS2-dependent viral control in human infection\", \"Signaling pathway downstream of DAP12 specific to KIR2DS2 not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5, 10, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DAP12\", \"HLA-C*0102\", \"KIR2DL2\"],\n    \"other_free_text\": []\n  }\n}\n```"}